Avista Therapeutics Partners with Roche to Develop Next-Generation AAV Gene Therapy Vectors for Ocular Diseases

Julia Wiecek
19 July 2022
Collaborations, Mergers & Acquisitions
Gene Therapy
Avista Therapeutics, known for its work in developing innovative gene therapies for retinal diseases, has announced a partnership with one of the world’s largest biotech companies, Roche, in hopes to develop AAV gene therapy vectors for ocular diseases.

This new partnership announced on July 19th, 2022, will see Avista’s single-cell AAV engineering platform technology be applied in the development of intravitreal AAV capsids, that match a capsid profile defined by Roche.

Funded with an upfront payment of $7.5 million, if successful, Avista can expect to receive additional payments during the research phase of the partnership. It is currently predicted that the total potential deal value may exceed $1 billion.

How are you enjoying this blog post? Let us know your thoughts, here >>

Avista was built on the research of leading experts in viral vector development and clinical ophthalmology, and, has long searched for a business partner to push their AAV gene therapy vectors into the marketing world.


Robert Lin, CEO of Avista Therapeutics has stated on behalf of the company, “We are excited to enter into this collaboration with Roche, a global leader in health care […] This collaboration will complement our in-house pipeline and will accelerate the delivery of transformative therapies to patients.”

Under the agreement, Roche will have the legal right to evaluate and license novel capsids from Avista.

Roche is to lead the preclinical and clinical trials, as well as the commercialization activities for gene therapy programs using these novel capsids.

Dr. Lin, adds that “Traditional therapies for retinal dystrophies address only symptoms and complications, neglecting the underlying biology of the diseases. Avista was founded to solve this problem, and our innovative scAAVengr platform allows us to deliver gene therapy payloads through intravitreal injection to treat a full range of retinal diseases with reduced immunogenicity.”

Source: Avista Press Release



While we have you…

We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.